Hughes T - Search Results

1

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Müller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ES, Press RD, Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NC. White HE, et al. Among authors: hughes t. Blood. 2010 Nov 25;116(22):e111-7. doi: 10.1182/blood-2010-06-291641. Epub 2010 Aug 18. Blood. 2010. PMID: 20720184 Free article.

2

Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation.

Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Cullis JO, et al. Among authors: hughes tp. Blood. 1992 Mar 1;79(5):1379-81. Blood. 1992. PMID: 1536963 Free article. No abstract available.

3

p53 in chronic myeloid leukemia cell lines.

Bi S, Hughes T, Bungey J, Chase A, de Fabritiis P, Goldman JM. Bi S, et al. Among authors: hughes t. Leukemia. 1992 Aug;6(8):839-42. Leukemia. 1992. PMID: 1640738

4

Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse.

Hughes TP, O'Shea P, Morgan G, Martiat P, Goldman JM. Hughes TP, et al. Bone Marrow Transplant. 1991;7 Suppl 2:23. Bone Marrow Transplant. 1991. PMID: 1878700 No abstract available.

5

Improved results with PCR for chronic myeloid leukaemia.

Hughes T, Goldman JM. Hughes T, et al. Lancet. 1990 Sep 29;336(8718):812. doi: 10.1016/0140-6736(90)93275-t. Lancet. 1990. PMID: 1976169 Clinical Trial. No abstract available.

6

Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse.

Hughes TP, Morgan GJ, Martiat P, Goldman JM. Hughes TP, et al. Blood. 1991 Feb 15;77(4):874-8. Blood. 1991. PMID: 1993225 Free article.

7

Detection and significance of minimal residual disease in patients with leukaemia and lymphoma.

Goldman JM, Hughes T. Goldman JM, et al. Among authors: hughes t. Bone Marrow Transplant. 1991;7 Suppl 1:66-9. Bone Marrow Transplant. 1991. PMID: 2043891 Review. No abstract available.

8

Biological importance of residual leukaemic cells after BMT for CML: does the polymerase chain reaction help?

Hughes TP, Goldman JM. Hughes TP, et al. Bone Marrow Transplant. 1990 Jan;5(1):3-6. Bone Marrow Transplant. 1990. PMID: 2404529 Review.

9

Polymerase chain reaction for detection of residual leukaemia.

Morgan GJ, Hughes T, Janssen JW, Gow J, Guo AP, Goldman JM, Wiedemann LM, Bartram CR. Morgan GJ, et al. Among authors: hughes t. Lancet. 1989 Apr 29;1(8644):928-9. doi: 10.1016/s0140-6736(89)92508-7. Lancet. 1989. PMID: 2565420

10

Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse.

Cross NC, Hughes TP, Feng L, O'Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM. Cross NC, et al. Among authors: hughes tp. Br J Haematol. 1993 May;84(1):67-74. doi: 10.1111/j.1365-2141.1993.tb03026.x. Br J Haematol. 1993. PMID: 8338780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,966 results

Search Page